Stem Cell and Derivatives

<p>3,5-Bis(4-nitrophenoxy)benzoic acid (Compound W) is an inhibitor of γ-secretase. It decreases the released levels of Aβ42 and notch-1 Aβ-like peptide 25.</p>

<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>

<p>LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 (IC50 &lt; 2 μM)</p>

LSKL, Inhibitor of Thrombospondin TSP-1 acetate is activation of TGF-β .

<p>Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.</p>

SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.

<p>Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.</p>

<p>TBB (NSC-231634)(NSC-231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2).</p>

<p>ITD-1 is a potent and highly selective TGFβ pathway inhibitor.</p>

<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>

<p>Galunisertib (LY2157299) is a selective TGF-β receptor type I (TGF-βRI) inhibitor. Galunisertib has antitumor activity. Cost-effective and quality-assured.</p>

<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: &lt;3 nM and0.45 nM).</p>

<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>

<p>BML-284 (Wnt agonist 1) is a potent, selective and , cell-permeable Wnt signaling activator.</p>

<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>

<p>MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.</p>

<p>NCC007 is a novel CKIα and CKIδ dual inhibitors by structural modification of N9 and C2 position of longdaysin.</p>

<p>Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic</p>

<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>

<p>Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.</p>

<p>BML-284 hydrochloride (Wnt agonist 1 HCL) is a potent, selective Wnt canonical signaling activator and tubulin polymerization inhibitor.</p>

<p>LH846 is a selective inhibitor of CK1δ (IC50 values are 290 nM, 1.3 uM and 2.5 uM for CK1δ, ε and α); exhibits no inhibitory activity at CK2.</p>

<p>ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.</p>

<p>PF-04802367 is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay.</p>

<p>WAY262611 is a Wnt/β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay.</p>

<p>MSAB inhibits Wnt/β-catenin by binding to β-catenin and inducing its breakdown.</p>

<p>Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.</p>

<p>Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.</p>

<p>IWP L6 (Porcn Inhibitor III) is an extremely effective Porcn inhibitor (EC50: 0.5 nM).</p>

<p>PF-4800567 is a selective inhibitor of casein kinase 1ε (CK1ε; IC50 = 32 nM) with greater than 20-fold selectivity over CK1δ.</p>

<p>SD-208 (ALK5 Inhibitor V), a selective TGF-βRI (ALK5) inhibitor (IC50: 48 nM), is &gt;100-fold selectivity over TGF-βRII.</p>

<p>TED-347 is an irreversible and covalent inhibitor of TEAD4-Yap1 protein-protein interaction(EC50 of 5.9 μM), and inhibits glioblastoma cell viability.</p>

<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>

<p>Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.</p>

<p>PF-5274857: selective hedgehog pathway inhibitor (IC50: 5.8 nM, Ki: 4.6 nM), treats brain tumors, crosses blood-brain barrier, orally stable.</p>

<p>SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.</p>

<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>

<p>GSK269962A (GSK269962A HCl) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.</p>

<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's &gt; 1000</p>

<p>IWP-4 (Inhibitor of Wnt Production-4) is a potent Wnt inhibitor.</p>

<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>

<p>JAK-IN-5 hydrochloride is a JAK inhibitor [1].</p>

<p>GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K, and a dramatically improved P450 profile.</p>

<p>Netarsudil mesylate (AR-13324 mesylate) is a Rho-related protein kinase inhibitor used to study glaucoma and hypertension.</p>

<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Cys-C, and the Human Cys-C standard plate wells that pre-coated using protein-related techniques are provided separately. Standard/Sample Diluent Buffer or samples are added to the appropriate microtiter plate wells ,then added a HRP-conjugated antibody specific to Human Cys-C. After TMB substrate solution is added, only those wells that contain Human Cys-C and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>CHIR 98024: strong GSK-3α/β blocker, IC50 0.65/0.58 nM, selective over Cdc2/ERK2.</p>

<p>PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.Cost-effective and quality-assured.</p>

<p>Potent oral TEAD-YAP/TAZ inhibitor-2 with 3 nM EC50; exhibits anti-proliferative and antitumor effects.</p>

<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 &lt; 200 nM.</p>